Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Turnover Ratios
Average No. Days
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The operational activity ratios exhibit a consistent trend toward reduced efficiency in the conversion of assets into cash over the analyzed period. The most prominent shift is observed in the significant elongation of the operating and cash conversion cycles, driven primarily by a substantial slowdown in inventory movement.
- Inventory Management Efficiency
- A sustained decline in inventory turnover is evident, falling from 1.93 in March 2022 to 0.78 by September 2026. This trend is mirrored by the average inventory processing period, which expanded from 189 days to 469 days. This indicates a marked increase in the time required to move products through the production and sales pipeline, suggesting either strategic stockpiling or a deceleration in sales relative to inventory accumulation.
- Receivables and Payables Dynamics
- Receivables turnover has remained relatively stable compared to inventory, though it shows a slight downward trajectory from 4.64 to 3.91. The average receivable collection period fluctuated moderately, ending at 93 days, which indicates a consistent ability to collect payments from customers. Conversely, payables turnover decreased from 5.24 to 2.44, while the average payables payment period more than doubled, rising from 70 days in March 2022 to 149 days by September 2026. This suggests a strategic shift toward extending payment terms with suppliers to preserve liquidity.
- Operating and Cash Conversion Cycles
- The operating cycle has expanded significantly, increasing from 268 days to 562 days. This expansion is almost entirely attributable to the increased inventory processing time. Despite the company's efforts to offset this by extending its payables payment period, the cash conversion cycle has still increased substantially, rising from 198 days to 413 days. This indicates a growing gap between the cash outflow for production and the cash inflow from sales.
- Working Capital Utilization
- Working capital turnover demonstrates extreme volatility throughout the period, with peaks reaching 31.84 and troughs falling to 2.71. This irregularity suggests significant fluctuations in the relationship between net sales and the investment in current assets minus current liabilities, reflecting potential shifts in short-term financing strategies or irregular spikes in operational volume.
In summary, the data reveals a widening gap in the cash conversion process. While receivables management remains stable, the substantial increase in the inventory processing period has become the primary driver of operational inefficiency, which is only partially mitigated by the strategic extension of supplier payment terms.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Inventory Turnover
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Cost of sales | 3,933) | 3,268) | 3,577) | 3,372) | 3,008) | 2,448) | 2,224) | 2,404) | 2,171) | 2,170) | 1,674) | 1,788) | 1,860) | 1,807) | 1,627) | 1,548) | 1,579) | 1,431) | 2,072) | ||||||
| Inventories | 18,194) | 16,793) | 14,529) | 13,744) | 12,180) | 11,014) | 9,311) | 7,589) | 7,460) | 6,482) | 6,102) | 5,773) | 4,901) | 4,799) | 4,545) | 4,310) | 3,831) | 3,899) | 3,893) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Inventory turnover1 | 0.78 | 0.79 | 0.85 | 0.80 | 0.83 | 0.84 | 0.96 | 1.11 | 1.05 | 1.16 | 1.17 | 1.23 | 1.40 | 1.37 | 1.36 | 1.54 | 1.86 | 1.79 | 1.93 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Inventory Turnover, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | 3.27 | 3.58 | 3.65 | 3.68 | 3.65 | 3.42 | 3.71 | 4.04 | 4.09 | 4.86 | 4.83 | 4.98 | 4.74 | 4.30 | 4.53 | 4.87 | 5.54 | 4.99 | 4.96 | ||||||
| Amgen Inc. | — | 1.87 | 1.91 | 1.93 | 1.92 | 1.88 | 1.88 | 1.84 | 1.75 | 1.42 | 1.14 | 0.89 | 1.41 | 1.38 | 1.31 | 1.30 | 1.34 | 1.40 | 1.48 | ||||||
| Bristol-Myers Squibb Co. | 5.69 | 5.36 | 5.20 | 5.18 | 5.31 | 5.18 | 5.28 | 5.46 | 3.57 | 3.72 | 3.70 | 4.02 | 4.33 | 4.39 | 3.93 | 4.33 | 4.77 | 4.59 | 4.55 | ||||||
| Danaher Corp. | 3.38 | 3.20 | 3.90 | 4.04 | 3.67 | 3.60 | 3.79 | 4.15 | 3.60 | 3.59 | 3.73 | 3.80 | 3.53 | 3.58 | 3.50 | 4.03 | 3.80 | 3.71 | 3.87 | ||||||
| Gilead Sciences Inc. | 3.28 | 3.18 | 3.21 | 3.51 | 3.47 | 3.40 | 3.55 | 3.66 | 3.62 | 3.33 | 3.59 | 3.64 | 3.49 | 3.45 | 3.57 | 3.75 | 4.71 | 4.50 | 4.50 | ||||||
| Johnson & Johnson | 2.10 | 2.08 | 2.13 | 2.13 | 2.08 | 2.17 | 2.24 | 2.21 | 2.15 | 2.20 | 2.32 | 2.37 | 2.46 | 2.23 | 2.36 | 2.49 | 2.68 | 2.69 | 2.77 | ||||||
| Merck & Co. Inc. | — | 2.90 | 2.65 | 2.46 | 2.27 | 2.25 | 2.43 | 2.49 | 2.45 | 2.39 | 2.42 | 2.54 | 2.63 | 2.66 | 2.72 | 2.95 | 3.10 | 3.06 | 2.74 | ||||||
| Pfizer Inc. | 1.69 | 1.72 | 1.57 | 1.51 | 1.46 | 1.52 | 1.60 | 1.65 | 1.66 | 2.05 | 2.15 | 2.45 | 2.65 | 2.31 | 3.07 | 3.82 | 3.62 | 3.66 | 3.67 | ||||||
| Regeneron Pharmaceuticals Inc. | 0.83 | 0.76 | 0.74 | 0.66 | 0.64 | 0.64 | 0.63 | 0.64 | 0.64 | 0.65 | 0.66 | 0.70 | 0.72 | 0.69 | 0.67 | 0.65 | 0.83 | 0.96 | 1.27 | ||||||
| Thermo Fisher Scientific Inc. | 4.94 | 4.87 | 4.87 | 4.85 | 4.47 | 4.57 | 4.82 | 5.06 | 4.62 | 4.83 | 4.93 | 5.06 | 4.83 | 4.64 | 4.62 | 4.60 | 4.29 | 4.03 | 3.87 | ||||||
| Vertex Pharmaceuticals Inc. | 0.83 | 1.00 | 0.95 | 0.98 | 0.99 | 1.06 | 1.14 | 1.27 | 1.37 | 1.53 | 1.65 | 1.71 | 1.71 | 1.90 | 2.06 | 2.35 | 2.69 | 2.70 | 2.83 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Inventory turnover
= (Cost of salesQ3 2026
+ Cost of salesQ2 2026
+ Cost of salesQ1 2026
+ Cost of salesQ4 2025)
÷ Inventories
= (3,933 + 3,268 + 3,577 + 3,372)
÷ 18,194 = 0.78
2 Click competitor name to see calculations.
A sustained decline in inventory turnover is evident over the period from March 31, 2022, to September 30, 2026. While the cost of sales increased substantially over this timeframe, the growth in total inventories significantly outpaced the expansion of sales costs, leading to a consistent reduction in the efficiency of inventory movement.
- Inventory Turnover Ratio Trends
- The inventory turnover ratio exhibits a continuous downward trajectory, falling from 1.93 in March 2022 to 0.78 by September 2026. A critical threshold was crossed in the first quarter of 2025, where the ratio dropped below 1.00, indicating that the company's average inventory levels began to exceed its quarterly cost of sales. This trend suggests a lengthening of the cash-to-cash cycle and a potential increase in carrying costs.
- Inventory Accumulation
- Inventories grew aggressively, increasing from 3,893 million USD in March 2022 to 18,194 million USD by September 2026. The rate of accumulation accelerated sharply beginning in 2024, with inventories nearly doubling between December 2023 and December 2024, and continuing to rise steeply throughout 2025 and 2026. This rapid build-up indicates a strategic shift toward higher stock levels, possibly to support product launches or to mitigate supply chain risks.
- Cost of Sales Analysis
- The cost of sales showed a general upward trend, particularly from 2024 onwards. After fluctuating between 1,431 million USD and 2,072 million USD in 2022, expenditures rose to 3,933 million USD by September 2026. Despite this growth in operating volume, the cost of sales did not scale proportionally with the inventory investment, which directly contributed to the deterioration of the turnover ratio.
The divergence between the rapid expansion of inventory assets and the more moderate growth in cost of sales highlights a significant shift in operating activity. The transition from a turnover ratio of 1.93 to 0.78 reflects a move toward a much heavier inventory position, which may signal an anticipation of significantly higher future demand or an inefficiency in inventory management processes during the scaling phase.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Receivables Turnover
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Revenue | 24,397) | 22,974) | 19,799) | 19,292) | 17,601) | 15,558) | 12,729) | 13,533) | 11,439) | 11,303) | 8,768) | 9,353) | 9,499) | 8,312) | 6,960) | 7,302) | 6,942) | 6,488) | 7,810) | ||||||
| Accounts receivable | 22,089) | 20,083) | 18,429) | 17,760) | 16,107) | 14,170) | 12,037) | 11,006) | 10,295) | 11,028) | 7,886) | 9,091) | 8,167) | 7,516) | 7,526) | 6,896) | 6,715) | 6,365) | 6,323) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Receivables turnover1 | 3.91 | 3.97 | 3.92 | 3.67 | 3.69 | 3.76 | 4.07 | 4.09 | 3.97 | 3.53 | 4.56 | 3.75 | 3.93 | 3.93 | 3.68 | 4.14 | 4.35 | 4.57 | 4.64 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | 4.89 | 4.66 | 5.03 | 4.86 | 4.67 | 4.62 | 4.60 | 5.16 | 4.84 | 4.69 | 4.55 | 4.87 | 4.83 | 4.88 | 4.95 | 5.16 | 5.38 | 5.10 | 5.29 | ||||||
| Amgen Inc. | — | 3.55 | 3.88 | 3.67 | 4.06 | 3.85 | 4.03 | 4.72 | 4.26 | 4.26 | 4.16 | 3.70 | 4.17 | 4.34 | 4.34 | 4.46 | 4.60 | 4.62 | 4.81 | ||||||
| Danaher Corp. | 6.21 | 6.33 | 6.49 | 6.28 | 6.46 | 6.74 | 6.79 | 6.75 | 6.77 | 7.15 | 7.02 | 6.09 | 6.15 | 6.64 | 6.89 | 6.40 | 7.09 | 6.81 | 6.87 | ||||||
| Gilead Sciences Inc. | 6.14 | 5.90 | 6.17 | 5.89 | 5.60 | 6.01 | 6.51 | 6.47 | 6.14 | 5.92 | 5.84 | 5.78 | 5.68 | 6.43 | 6.43 | 5.65 | 6.16 | 6.60 | 7.18 | ||||||
| Johnson & Johnson | 5.23 | 5.14 | 5.44 | 5.48 | 5.23 | 5.08 | 5.58 | 5.98 | 5.42 | 5.48 | 5.73 | 5.73 | 5.91 | 5.36 | 5.65 | 5.88 | 6.04 | 5.92 | 6.08 | ||||||
| Merck & Co. Inc. | — | 5.30 | 5.39 | 5.52 | 5.30 | 5.37 | 5.92 | 6.24 | 5.55 | 5.37 | 5.40 | 5.81 | 5.71 | 5.29 | 5.56 | 6.27 | 6.22 | 5.93 | 5.49 | ||||||
| Pfizer Inc. | 4.48 | 5.10 | 5.03 | 5.27 | 4.40 | 5.29 | 5.27 | 5.55 | 4.18 | 4.93 | 5.09 | 5.33 | 6.25 | 7.66 | 7.57 | 9.16 | 6.21 | 6.68 | 6.99 | ||||||
| Regeneron Pharmaceuticals Inc. | 2.23 | 2.37 | 2.60 | 2.50 | 2.51 | 2.53 | 2.53 | 2.29 | 2.27 | 2.36 | 2.51 | 2.31 | 2.35 | 2.47 | 2.42 | 2.28 | 2.47 | 2.76 | 3.41 | ||||||
| Thermo Fisher Scientific Inc. | 4.92 | 4.90 | 4.91 | 5.01 | 4.91 | 5.03 | 5.07 | 5.23 | 5.13 | 5.33 | 5.36 | 5.21 | 5.19 | 5.43 | 5.53 | 5.53 | 5.76 | 5.53 | 5.21 | ||||||
| Vertex Pharmaceuticals Inc. | 5.60 | 5.90 | 6.12 | 5.85 | 6.02 | 6.03 | 6.15 | 6.85 | 6.07 | 6.24 | 5.68 | 6.31 | 6.27 | 6.11 | 5.95 | 6.19 | 6.28 | 6.26 | 6.15 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Receivables turnover
= (RevenueQ3 2026
+ RevenueQ2 2026
+ RevenueQ1 2026
+ RevenueQ4 2025)
÷ Accounts receivable
= (24,397 + 22,974 + 19,799 + 19,292)
÷ 22,089 = 3.91
2 Click competitor name to see calculations.
The financial trajectory from March 2022 through September 2026 is characterized by substantial revenue expansion accompanied by a proportional increase in accounts receivable, resulting in a general contraction of the receivables turnover ratio over the long term.
- Revenue and Accounts Receivable Growth
- Revenue exhibited an aggressive upward trend, rising from 7,810 million US$ in March 2022 to 24,397 million US$ by September 2026. Parallel to this growth, accounts receivable increased from 6,323 million US$ to 22,089 million US$. Because the growth in receivables slightly outpaced the growth in revenue, the efficiency of converting credit sales into cash diminished over the analyzed period.
- Receivables Turnover Ratio Dynamics
- The receivables turnover ratio began at 4.64 in March 2022 and concluded at 3.91 in September 2026. A period of consistent decline was observed through March 2023, reaching 3.68. Although a sharp recovery to 4.56 occurred in March 2024, the ratio subsequently entered a period of volatility and stabilization, fluctuating between a low of 3.53 in June 2024 and a high of 4.09 in December 2023, before settling in the 3.90 range by late 2026.
- Collection Efficiency Analysis
- The overall decline in the turnover ratio indicates a lengthening of the average collection period. The divergence between the rapid escalation of revenue and the slower stabilization of the turnover ratio suggests that the company may be extending more liberal credit terms to support its growth or experiencing slower payment cycles from customers as the volume of business expands. Despite these pressures, the ratio remained relatively resilient, never falling below 3.53.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Payables Turnover
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Cost of sales | 3,933) | 3,268) | 3,577) | 3,372) | 3,008) | 2,448) | 2,224) | 2,404) | 2,171) | 2,170) | 1,674) | 1,788) | 1,860) | 1,807) | 1,627) | 1,548) | 1,579) | 1,431) | 2,072) | ||||||
| Accounts payable | 5,793) | 6,112) | 5,029) | 5,379) | 4,262) | 4,076) | 3,442) | 3,229) | 2,887) | 2,925) | 2,474) | 2,599) | 2,435) | 2,474) | 2,016) | 1,931) | 1,683) | 1,659) | 1,433) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Payables turnover1 | 2.44 | 2.16 | 2.47 | 2.05 | 2.37 | 2.27 | 2.61 | 2.61 | 2.70 | 2.56 | 2.88 | 2.73 | 2.81 | 2.65 | 3.07 | 3.43 | 4.24 | 4.21 | 5.24 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Payables Turnover, Competitors2 | |||||||||||||||||||||||||
| Amgen Inc. | — | 4.05 | 4.02 | 5.09 | 4.29 | 4.12 | 5.25 | 6.74 | 5.99 | 5.01 | 6.10 | 5.32 | 5.22 | 5.67 | 4.97 | 4.08 | 5.30 | 5.09 | 4.65 | ||||||
| Bristol-Myers Squibb Co. | 3.33 | 3.53 | 3.38 | 3.90 | 3.42 | 2.61 | 3.52 | 3.88 | 3.43 | 3.05 | 3.12 | 3.28 | 3.75 | 3.38 | 3.20 | 3.33 | 3.82 | 3.41 | 3.25 | ||||||
| Danaher Corp. | 6.09 | 5.72 | 5.68 | 5.45 | 5.78 | 5.62 | 5.57 | 5.52 | 6.04 | 5.84 | 5.88 | 5.58 | 5.63 | 5.82 | 5.68 | 5.45 | 5.61 | 5.00 | 5.04 | ||||||
| Gilead Sciences Inc. | 6.66 | 9.22 | 9.52 | 8.72 | 7.66 | 10.65 | 8.47 | 7.50 | 7.49 | 12.57 | 10.69 | 11.81 | 9.90 | 9.06 | 8.99 | 6.25 | 11.22 | 11.89 | 11.43 | ||||||
| Johnson & Johnson | 3.46 | 3.41 | 2.96 | 2.52 | 3.06 | 3.07 | 2.97 | 2.66 | 3.03 | 3.03 | 3.23 | 2.76 | 3.29 | 2.75 | 3.05 | 2.66 | 3.08 | 3.15 | 3.26 | ||||||
| Merck & Co. Inc. | — | 4.70 | 4.44 | 3.72 | 3.53 | 3.82 | 3.98 | 3.72 | 4.26 | 4.39 | 4.48 | 4.11 | 4.59 | 4.58 | 4.34 | 4.08 | 5.16 | 4.86 | 4.25 | ||||||
| Pfizer Inc. | 4.16 | 3.73 | 3.72 | 3.07 | 3.32 | 3.44 | 3.30 | 3.17 | 3.67 | 4.60 | 4.19 | 3.72 | 5.07 | 3.92 | 4.78 | 5.04 | 5.49 | 6.17 | 6.66 | ||||||
| Regeneron Pharmaceuticals Inc. | 2.11 | 2.03 | 2.24 | 2.24 | 2.30 | 2.83 | 2.84 | 2.50 | 3.87 | 3.32 | 2.67 | 2.99 | 3.43 | 3.14 | 2.69 | 2.65 | 3.74 | 4.00 | 5.39 | ||||||
| Thermo Fisher Scientific Inc. | 9.04 | 8.39 | 8.00 | 7.27 | 8.23 | 8.53 | 8.25 | 8.18 | 9.63 | 9.85 | 9.91 | 8.97 | 10.41 | 10.82 | 9.35 | 7.67 | 9.93 | 8.84 | 7.96 | ||||||
| Vertex Pharmaceuticals Inc. | 3.97 | 4.10 | 3.44 | 3.58 | 3.83 | 3.59 | 3.49 | 3.71 | 3.73 | 4.27 | 3.81 | 3.46 | 3.13 | 3.16 | 3.41 | 3.55 | 8.23 | 5.01 | 5.52 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Payables turnover
= (Cost of salesQ3 2026
+ Cost of salesQ2 2026
+ Cost of salesQ1 2026
+ Cost of salesQ4 2025)
÷ Accounts payable
= (3,933 + 3,268 + 3,577 + 3,372)
÷ 5,793 = 2.44
2 Click competitor name to see calculations.
An analysis of the operating activity ratios reveals a consistent long-term decline in the payables turnover ratio, occurring alongside a significant expansion in both the cost of sales and total accounts payable.
- Cost of Sales and Accounts Payable Trends
- Cost of sales exhibited a sustained upward trajectory, rising from 2,072 million US$ in March 2022 to 3,933 million US$ by September 2026. During the same period, accounts payable grew more aggressively, increasing from 1,433 million US$ to 5,793 million US$. The disproportionate growth of liabilities relative to the cost of sales suggests a strategic shift in how the company manages its short-term obligations.
- Payables Turnover Ratio Analysis
- The payables turnover ratio experienced a marked decrease, falling from a high of 5.24 in March 2022 to a range between 2.16 and 2.47 during the final year of the observed period. The most significant contraction occurred between March 2022 and June 2023, where the ratio dropped from 5.24 to 2.65. From June 2023 onward, the ratio stabilized, fluctuating within a narrower band between 2.05 and 2.88.
- Operational Implications
- The steady decline in the turnover ratio indicates an extension of the payment cycle to suppliers. By reducing the frequency with which accounts payable are settled, the company has increased its days payable outstanding. This pattern is indicative of a working capital management strategy designed to preserve cash flow and leverage supplier credit to support operational growth.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Working Capital Turnover
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Current assets | 65,263) | 64,672) | 54,835) | 55,629) | 62,071) | 49,854) | 41,261) | 32,740) | 31,415) | 30,204) | 25,189) | 25,727) | 23,007) | 21,332) | 20,811) | 18,035) | 17,640) | 17,115) | 16,965) | ||||||
| Less: Current liabilities | 46,996) | 47,741) | 36,634) | 35,228) | 40,141) | 39,020) | 30,068) | 28,377) | 24,674) | 27,121) | 18,598) | 27,293) | 21,998) | 18,915) | 16,010) | 17,138) | 15,653) | 15,621) | 13,386) | ||||||
| Working capital | 18,267) | 16,931) | 18,201) | 20,401) | 21,930) | 10,834) | 11,193) | 4,363) | 6,741) | 3,083) | 6,591) | (1,566) | 1,009) | 2,417) | 4,801) | 896) | 1,987) | 1,495) | 3,579) | ||||||
| Revenue | 24,397) | 22,974) | 19,799) | 19,292) | 17,601) | 15,558) | 12,729) | 13,533) | 11,439) | 11,303) | 8,768) | 9,353) | 9,499) | 8,312) | 6,960) | 7,302) | 6,942) | 6,488) | 7,810) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Working capital turnover1 | 4.73 | 4.71 | 3.97 | 3.19 | 2.71 | 4.92 | 4.38 | 10.32 | 6.06 | 12.62 | 5.45 | — | 31.79 | 12.21 | 5.77 | 31.84 | 14.71 | 19.45 | 8.19 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Amgen Inc. | — | 3.83 | 5.44 | 9.85 | 5.66 | 5.35 | 8.36 | 5.40 | 4.83 | 5.19 | 3.39 | 2.25 | 0.81 | 0.84 | 0.82 | 3.82 | 2.52 | 3.67 | 4.34 | ||||||
| Bristol-Myers Squibb Co. | 4.40 | 4.81 | 5.84 | 7.83 | 6.20 | 8.09 | 6.87 | 7.79 | 8.49 | 12.50 | 15.56 | 4.60 | 10.47 | 5.53 | 5.55 | 8.30 | 5.75 | 4.92 | 6.24 | ||||||
| Danaher Corp. | 4.46 | 4.76 | 3.83 | 4.13 | 7.39 | 5.71 | 8.27 | 8.85 | 8.73 | 8.10 | 3.60 | 4.22 | 2.18 | 3.08 | 3.81 | 4.20 | 5.00 | 5.43 | 5.91 | ||||||
| Gilead Sciences Inc. | 6.76 | 10.20 | 3.19 | 4.43 | 5.12 | 8.14 | 6.27 | 3.99 | 9.22 | 17.98 | 26.58 | 5.61 | 6.74 | 84.15 | 9.14 | 8.42 | 8.56 | 6.87 | 6.68 | ||||||
| Johnson & Johnson | 111.11 | 20.07 | 66.14 | 62.88 | 24.63 | 284.99 | 6.10 | 15.94 | 58.86 | 22.29 | 10.35 | 11.81 | 9.37 | 14.06 | 23.02 | — | 4.88 | 5.02 | 5.57 | ||||||
| Merck & Co. Inc. | — | 7.44 | 8.15 | 4.28 | 3.39 | 5.77 | 6.19 | 6.19 | 5.86 | 5.14 | 9.68 | 9.29 | 6.69 | 8.86 | 5.63 | 5.16 | 5.58 | 6.39 | 6.09 | ||||||
| Pfizer Inc. | 4.79 | 7.31 | 7.47 | 10.58 | 6.08 | 10.68 | 6.64 | 8.64 | 5,036.00 | — | 29.17 | — | 1.62 | 2.03 | 6.89 | 11.00 | 3.83 | 5.05 | 6.10 | ||||||
| Regeneron Pharmaceuticals Inc. | 1.16 | 1.20 | 1.14 | 1.05 | 1.05 | 1.08 | 1.01 | 0.97 | 0.88 | 0.87 | 0.86 | 0.82 | 0.87 | 0.92 | 0.90 | 0.96 | 1.09 | 1.14 | 1.46 | ||||||
| Thermo Fisher Scientific Inc. | 4.14 | 5.59 | 5.87 | 3.30 | 5.90 | 3.64 | 4.20 | 4.87 | 4.61 | 3.96 | 4.38 | 4.05 | 4.86 | 7.40 | 10.13 | 5.46 | 5.40 | 6.03 | 6.13 | ||||||
| Vertex Pharmaceuticals Inc. | 1.94 | 1.46 | 1.56 | 1.64 | 1.92 | 1.82 | 1.78 | 1.83 | 1.82 | 1.92 | 1.07 | 0.93 | 0.87 | 0.90 | 0.93 | 0.85 | 0.90 | 0.93 | 0.97 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Working capital turnover
= (RevenueQ3 2026
+ RevenueQ2 2026
+ RevenueQ1 2026
+ RevenueQ4 2025)
÷ Working capital
= (24,397 + 22,974 + 19,799 + 19,292)
÷ 18,267 = 4.73
2 Click competitor name to see calculations.
The financial trajectory between March 2022 and September 2026 is characterized by substantial revenue growth coupled with a significant expansion in working capital, resulting in a general decline in working capital turnover efficiency.
- Revenue Growth Trends
- A consistent upward trend in revenue is observed, progressing from 7,810 million USD in March 2022 to 24,397 million USD by September 2026. The growth accelerated notably starting in June 2024, with quarterly revenues consistently exceeding 11,000 million USD from that point forward and peaking at the end of the analyzed period.
- Working Capital Volatility and Expansion
- Working capital exhibited extreme volatility in the initial phase, reaching a low of 896 million USD in December 2022 and dipping into negative territory (-1,566 million USD) in December 2023. However, a fundamental shift occurred in 2024 and 2025, where working capital scaled aggressively. The figure rose from 6,591 million USD in March 2024 to a peak of 21,930 million USD in September 2025, indicating a substantial increase in the net current assets utilized to support operations.
- Working Capital Turnover Analysis
- The turnover ratio showed high instability during 2022 and 2023, with peaks as high as 31.84. These spikes were primarily driven by periods of exceptionally low working capital relative to revenue. As working capital expanded rapidly from 2024 onward, the turnover ratio experienced a marked compression. The ratio declined from a high of 12.62 in June 2024 to a low of 2.71 in September 2025. While the ratio showed slight recovery and stabilization between 3.97 and 4.73 in 2026, it remained significantly lower than the levels seen in the early part of the period.
- Operational Efficiency Insights
- The inverse relationship between the surging working capital and the declining turnover ratio suggests that revenue growth is being supported by a disproportionately larger investment in short-term assets. The shift from a lean working capital model (characterized by high turnover ratios in 2022-2023) to a more capital-intensive model in 2025-2026 indicates a change in the operating cycle or a strategic accumulation of liquidity and inventory to sustain higher sales volumes.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Average Inventory Processing Period
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Inventory turnover | 0.78 | 0.79 | 0.85 | 0.80 | 0.83 | 0.84 | 0.96 | 1.11 | 1.05 | 1.16 | 1.17 | 1.23 | 1.40 | 1.37 | 1.36 | 1.54 | 1.86 | 1.79 | 1.93 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||
| Average inventory processing period1 | 469 | 463 | 428 | 454 | 441 | 435 | 379 | 329 | 349 | 316 | 312 | 298 | 261 | 267 | 268 | 237 | 196 | 204 | 189 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | 112 | 102 | 100 | 99 | 100 | 107 | 98 | 90 | 89 | 75 | 75 | 73 | 77 | 85 | 81 | 75 | 66 | 73 | 74 | ||||||
| Amgen Inc. | — | 195 | 191 | 189 | 190 | 194 | 195 | 199 | 209 | 257 | 321 | 411 | 259 | 265 | 279 | 281 | 272 | 260 | 247 | ||||||
| Bristol-Myers Squibb Co. | 64 | 68 | 70 | 70 | 69 | 70 | 69 | 67 | 102 | 98 | 99 | 91 | 84 | 83 | 93 | 84 | 76 | 79 | 80 | ||||||
| Danaher Corp. | 108 | 114 | 94 | 90 | 99 | 101 | 96 | 88 | 101 | 102 | 98 | 96 | 104 | 102 | 104 | 91 | 96 | 98 | 94 | ||||||
| Gilead Sciences Inc. | 111 | 115 | 114 | 104 | 105 | 108 | 103 | 100 | 101 | 110 | 102 | 100 | 105 | 106 | 102 | 97 | 78 | 81 | 81 | ||||||
| Johnson & Johnson | 174 | 176 | 172 | 171 | 176 | 168 | 163 | 165 | 169 | 166 | 158 | 154 | 149 | 164 | 155 | 147 | 136 | 136 | 132 | ||||||
| Merck & Co. Inc. | — | 126 | 138 | 148 | 160 | 162 | 150 | 147 | 149 | 153 | 151 | 144 | 139 | 137 | 134 | 124 | 118 | 119 | 133 | ||||||
| Pfizer Inc. | 216 | 212 | 232 | 242 | 251 | 239 | 229 | 222 | 219 | 178 | 170 | 149 | 138 | 158 | 119 | 95 | 101 | 100 | 99 | ||||||
| Regeneron Pharmaceuticals Inc. | 439 | 479 | 491 | 556 | 571 | 570 | 582 | 572 | 573 | 562 | 553 | 519 | 508 | 532 | 549 | 562 | 440 | 379 | 287 | ||||||
| Thermo Fisher Scientific Inc. | 74 | 75 | 75 | 75 | 82 | 80 | 76 | 72 | 79 | 76 | 74 | 72 | 76 | 79 | 79 | 79 | 85 | 91 | 94 | ||||||
| Vertex Pharmaceuticals Inc. | 437 | 365 | 384 | 373 | 369 | 345 | 320 | 287 | 267 | 238 | 222 | 214 | 213 | 192 | 177 | 156 | 136 | 135 | 129 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 0.78 = 469
2 Click competitor name to see calculations.
The analysis reveals a significant and consistent deterioration in inventory efficiency over the observed period from March 2022 to September 2026. A clear inverse correlation exists between the inventory turnover ratio and the average inventory processing period, indicating a prolonged cycle in converting inventory into sales.
- Inventory Turnover Ratio Trend
- A continuous downward trajectory is observed, with the ratio declining from 1.93 in March 2022 to 0.78 by September 2026. This steady decrease suggests that inventory is being cycled through the business significantly slower than in previous periods, eventually falling below the 1.0 threshold during the final phases of the analyzed timeframe.
- Average Inventory Processing Period Expansion
- The number of days required to process inventory has increased substantially, rising from 189 days in March 2022 to 469 days by September 2026. This represents a total increase of 280 days in the processing cycle. The acceleration of this trend became particularly evident starting in March 2025, as the period surpassed 365 days and continued to climb toward the 469-day mark.
- Operational Efficiency Insights
- The simultaneous decline in turnover and the expansion of the processing period indicate a growing accumulation of inventory relative to the cost of goods sold. The transition from a processing period of approximately six months in early 2022 to over fifteen months by late 2026 suggests a fundamental shift in the operational cycle, potentially reflecting strategic stockpiling, production increases outpacing demand, or a change in the product lifecycle management.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Average Receivable Collection Period
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Receivables turnover | 3.91 | 3.97 | 3.92 | 3.67 | 3.69 | 3.76 | 4.07 | 4.09 | 3.97 | 3.53 | 4.56 | 3.75 | 3.93 | 3.93 | 3.68 | 4.14 | 4.35 | 4.57 | 4.64 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||
| Average receivable collection period1 | 93 | 92 | 93 | 99 | 99 | 97 | 90 | 89 | 92 | 103 | 80 | 97 | 93 | 93 | 99 | 88 | 84 | 80 | 79 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | 75 | 78 | 73 | 75 | 78 | 79 | 79 | 71 | 75 | 78 | 80 | 75 | 76 | 75 | 74 | 71 | 68 | 72 | 69 | ||||||
| Amgen Inc. | — | 103 | 94 | 99 | 90 | 95 | 91 | 77 | 86 | 86 | 88 | 99 | 88 | 84 | 84 | 82 | 79 | 79 | 76 | ||||||
| Danaher Corp. | 59 | 58 | 56 | 58 | 56 | 54 | 54 | 54 | 54 | 51 | 52 | 60 | 59 | 55 | 53 | 57 | 51 | 54 | 53 | ||||||
| Gilead Sciences Inc. | 59 | 62 | 59 | 62 | 65 | 61 | 56 | 56 | 59 | 62 | 62 | 63 | 64 | 57 | 57 | 65 | 59 | 55 | 51 | ||||||
| Johnson & Johnson | 70 | 71 | 67 | 67 | 70 | 72 | 65 | 61 | 67 | 67 | 64 | 64 | 62 | 68 | 65 | 62 | 60 | 62 | 60 | ||||||
| Merck & Co. Inc. | — | 69 | 68 | 66 | 69 | 68 | 62 | 58 | 66 | 68 | 68 | 63 | 64 | 69 | 66 | 58 | 59 | 62 | 66 | ||||||
| Pfizer Inc. | 81 | 72 | 73 | 69 | 83 | 69 | 69 | 66 | 87 | 74 | 72 | 69 | 58 | 48 | 48 | 40 | 59 | 55 | 52 | ||||||
| Regeneron Pharmaceuticals Inc. | 164 | 154 | 140 | 146 | 146 | 144 | 144 | 160 | 161 | 155 | 146 | 158 | 156 | 148 | 151 | 160 | 148 | 132 | 107 | ||||||
| Thermo Fisher Scientific Inc. | 74 | 74 | 74 | 73 | 74 | 73 | 72 | 70 | 71 | 68 | 68 | 70 | 70 | 67 | 66 | 66 | 63 | 66 | 70 | ||||||
| Vertex Pharmaceuticals Inc. | 65 | 62 | 60 | 62 | 61 | 61 | 59 | 53 | 60 | 58 | 64 | 58 | 58 | 60 | 61 | 59 | 58 | 58 | 59 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 3.91 = 93
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals a general extension in the time required to convert accounts receivable into cash over the observed period. A correlation exists between the decline in receivables turnover and the corresponding increase in the average receivable collection period, suggesting a shift in the efficiency of credit collection processes.
- Receivables Turnover Trends
- A gradual decline in the turnover ratio is observed from the initial period of March 2022, where the ratio stood at 4.64, reaching a low of 3.68 by March 2023. While a temporary recovery occurred in March 2024 with a peak of 4.56, the ratio subsequently stabilized within a narrow range between 3.53 and 4.09 throughout the remainder of the period, ending at 3.91 in September 2026.
- Average Receivable Collection Period
- The collection period demonstrated a steady upward trajectory during the first year, rising from 79 days in March 2022 to 99 days in March 2023. Following this period of increase, the metric exhibited significant volatility in 2024, fluctuating from a low of 80 days in March to a peak of 103 days in June. From December 2024 through September 2026, the collection period remained relatively stable, consistently oscillating between 90 and 99 days.
- Operational Efficiency Analysis
- The transition from a sub-80-day collection cycle in early 2022 to a consistent 90-plus-day cycle by 2026 indicates a slowing of the cash conversion cycle regarding receivables. The peak of 103 days in June 2024 represents the lowest point of efficiency in receivable management within the analyzed timeframe. Despite subsequent fluctuations, the company has not returned to the lower collection thresholds observed in 2022.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Operating Cycle
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Average inventory processing period | 469 | 463 | 428 | 454 | 441 | 435 | 379 | 329 | 349 | 316 | 312 | 298 | 261 | 267 | 268 | 237 | 196 | 204 | 189 | ||||||
| Average receivable collection period | 93 | 92 | 93 | 99 | 99 | 97 | 90 | 89 | 92 | 103 | 80 | 97 | 93 | 93 | 99 | 88 | 84 | 80 | 79 | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Operating cycle1 | 562 | 555 | 521 | 553 | 540 | 532 | 469 | 418 | 441 | 419 | 392 | 395 | 354 | 360 | 367 | 325 | 280 | 284 | 268 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Operating Cycle, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | 187 | 180 | 173 | 174 | 178 | 186 | 177 | 161 | 164 | 153 | 155 | 148 | 153 | 160 | 155 | 146 | 134 | 145 | 143 | ||||||
| Amgen Inc. | — | 298 | 285 | 288 | 280 | 289 | 286 | 276 | 295 | 343 | 409 | 510 | 347 | 349 | 363 | 363 | 351 | 339 | 323 | ||||||
| Danaher Corp. | 167 | 172 | 150 | 148 | 155 | 155 | 150 | 142 | 155 | 153 | 150 | 156 | 163 | 157 | 157 | 148 | 147 | 152 | 147 | ||||||
| Gilead Sciences Inc. | 170 | 177 | 173 | 166 | 170 | 169 | 159 | 156 | 160 | 172 | 164 | 163 | 169 | 163 | 159 | 162 | 137 | 136 | 132 | ||||||
| Johnson & Johnson | 244 | 247 | 239 | 238 | 246 | 240 | 228 | 226 | 236 | 233 | 222 | 218 | 211 | 232 | 220 | 209 | 196 | 198 | 192 | ||||||
| Merck & Co. Inc. | — | 195 | 206 | 214 | 229 | 230 | 212 | 205 | 215 | 221 | 219 | 207 | 203 | 206 | 200 | 182 | 177 | 181 | 199 | ||||||
| Pfizer Inc. | 297 | 284 | 305 | 311 | 334 | 308 | 298 | 288 | 306 | 252 | 242 | 218 | 196 | 206 | 167 | 135 | 160 | 155 | 151 | ||||||
| Regeneron Pharmaceuticals Inc. | 603 | 633 | 631 | 702 | 717 | 714 | 726 | 732 | 734 | 717 | 699 | 677 | 664 | 680 | 700 | 722 | 588 | 511 | 394 | ||||||
| Thermo Fisher Scientific Inc. | 148 | 149 | 149 | 148 | 156 | 153 | 148 | 142 | 150 | 144 | 142 | 142 | 146 | 146 | 145 | 145 | 148 | 157 | 164 | ||||||
| Vertex Pharmaceuticals Inc. | 502 | 427 | 444 | 435 | 430 | 406 | 379 | 340 | 327 | 296 | 286 | 272 | 271 | 252 | 238 | 215 | 194 | 193 | 188 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 469 + 93 = 562
2 Click competitor name to see calculations.
The operational efficiency regarding the conversion of assets into cash has experienced a significant decline over the analyzed period, characterized by a substantial and consistent extension of the overall operating cycle.
- Average Inventory Processing Period
- A pronounced upward trend is observed in the time required to process inventory. From a starting point of 189 days in March 2022, the period increased to 469 days by September 2026. The data indicates that the inventory processing timeframe more than doubled over the analyzed duration. Notable accelerations in this trend occurred between March 2024 and September 2025, where the period climbed from 312 days to 441 days, suggesting a marked slowdown in inventory turnover.
- Average Receivable Collection Period
- The collection period for receivables has remained relatively stable, exhibiting only minor fluctuations. Starting at 79 days in March 2022 and ending at 93 days in September 2026, the values generally oscillated between a low of 79 days and a peak of 103 days in June 2024. This relative constancy indicates that the efficiency of credit collections and accounts receivable management has not been the primary driver of changes in the overall operational cycle.
- Operating Cycle
- The total operating cycle expanded significantly from 268 days in March 2022 to 562 days by September 2026. This expansion is almost entirely attributable to the increase in the average inventory processing period. While the cycle showed brief periods of contraction—most notably in March 2024 and March 2026—the overarching trajectory is one of substantial growth, indicating a longer duration of capital being tied up in the operating process before being converted back into cash.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Average Payables Payment Period
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Payables turnover | 2.44 | 2.16 | 2.47 | 2.05 | 2.37 | 2.27 | 2.61 | 2.61 | 2.70 | 2.56 | 2.88 | 2.73 | 2.81 | 2.65 | 3.07 | 3.43 | 4.24 | 4.21 | 5.24 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||
| Average payables payment period1 | 149 | 169 | 148 | 178 | 154 | 161 | 140 | 140 | 135 | 142 | 127 | 134 | 130 | 138 | 119 | 106 | 86 | 87 | 70 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | |||||||||||||||||||||||||
| Amgen Inc. | — | 90 | 91 | 72 | 85 | 89 | 70 | 54 | 61 | 73 | 60 | 69 | 70 | 64 | 73 | 90 | 69 | 72 | 78 | ||||||
| Bristol-Myers Squibb Co. | 110 | 103 | 108 | 94 | 107 | 140 | 104 | 94 | 106 | 120 | 117 | 111 | 97 | 108 | 114 | 109 | 96 | 107 | 112 | ||||||
| Danaher Corp. | 60 | 64 | 64 | 67 | 63 | 65 | 66 | 66 | 60 | 63 | 62 | 65 | 65 | 63 | 64 | 67 | 65 | 73 | 72 | ||||||
| Gilead Sciences Inc. | 55 | 40 | 38 | 42 | 48 | 34 | 43 | 49 | 49 | 29 | 34 | 31 | 37 | 40 | 41 | 58 | 33 | 31 | 32 | ||||||
| Johnson & Johnson | 106 | 107 | 123 | 145 | 119 | 119 | 123 | 137 | 120 | 121 | 113 | 132 | 111 | 133 | 120 | 137 | 118 | 116 | 112 | ||||||
| Merck & Co. Inc. | — | 78 | 82 | 98 | 103 | 95 | 92 | 98 | 86 | 83 | 81 | 89 | 80 | 80 | 84 | 89 | 71 | 75 | 86 | ||||||
| Pfizer Inc. | 88 | 98 | 98 | 119 | 110 | 106 | 110 | 115 | 99 | 79 | 87 | 98 | 72 | 93 | 76 | 72 | 66 | 59 | 55 | ||||||
| Regeneron Pharmaceuticals Inc. | 173 | 180 | 163 | 163 | 158 | 129 | 129 | 146 | 94 | 110 | 137 | 122 | 106 | 116 | 136 | 138 | 98 | 91 | 68 | ||||||
| Thermo Fisher Scientific Inc. | 40 | 43 | 46 | 50 | 44 | 43 | 44 | 45 | 38 | 37 | 37 | 41 | 35 | 34 | 39 | 48 | 37 | 41 | 46 | ||||||
| Vertex Pharmaceuticals Inc. | 92 | 89 | 106 | 102 | 95 | 102 | 105 | 98 | 98 | 85 | 96 | 106 | 117 | 115 | 107 | 103 | 44 | 73 | 66 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 2.44 = 149
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals a consistent expansion in the time required to settle obligations with suppliers over the observed period. There is a clear inverse correlation between the payables turnover ratio and the average payables payment period, with the former trending downward while the latter trends upward.
- Payables Turnover Trend
- A significant decline in the payables turnover ratio is observed, falling from 5.24 in March 2022 to 2.44 by September 2026. The most rapid deceleration occurred throughout 2022, where the ratio dropped from 5.24 to 3.43. Following this initial decline, the ratio entered a period of relative stability between 2.56 and 3.07 throughout 2023 and 2024, before reaching a low of 2.05 in December 2025.
- Average Payables Payment Period Expansion
- The average payables payment period exhibits a marked upward trajectory, increasing from 70 days in March 2022 to a peak of 178 days in December 2025. This represents more than a twofold increase in the duration the company takes to pay its creditors. The expansion progressed through several stages: an initial jump to 106 days by the end of 2022, a sustained increase to the 130-140 day range during 2023 and 2024, and a final surge toward the end of 2025.
- Recent Volatility and Stabilization
- In the final quarters of the data set, a reversal of the expansion trend is evident. After peaking at 178 days in December 2025, the payment period decreased to 148 days in March 2026, rose slightly to 169 days in June 2026, and settled at 149 days by September 2026. This indicates a potential stabilization of supplier payment terms or a strategic adjustment in working capital management toward the end of the analysis period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Cash Conversion Cycle
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Average inventory processing period | 469 | 463 | 428 | 454 | 441 | 435 | 379 | 329 | 349 | 316 | 312 | 298 | 261 | 267 | 268 | 237 | 196 | 204 | 189 | ||||||
| Average receivable collection period | 93 | 92 | 93 | 99 | 99 | 97 | 90 | 89 | 92 | 103 | 80 | 97 | 93 | 93 | 99 | 88 | 84 | 80 | 79 | ||||||
| Average payables payment period | 149 | 169 | 148 | 178 | 154 | 161 | 140 | 140 | 135 | 142 | 127 | 134 | 130 | 138 | 119 | 106 | 86 | 87 | 70 | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Cash conversion cycle1 | 413 | 386 | 373 | 375 | 386 | 371 | 329 | 278 | 306 | 277 | 265 | 261 | 224 | 222 | 248 | 219 | 194 | 197 | 198 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | |||||||||||||||||||||||||
| Amgen Inc. | — | 208 | 194 | 216 | 195 | 200 | 216 | 222 | 234 | 270 | 349 | 441 | 277 | 285 | 290 | 273 | 282 | 267 | 245 | ||||||
| Danaher Corp. | 107 | 108 | 86 | 81 | 92 | 90 | 84 | 76 | 95 | 90 | 88 | 91 | 98 | 94 | 93 | 81 | 82 | 79 | 75 | ||||||
| Gilead Sciences Inc. | 115 | 137 | 135 | 124 | 122 | 135 | 116 | 107 | 111 | 143 | 130 | 132 | 132 | 123 | 118 | 104 | 104 | 105 | 100 | ||||||
| Johnson & Johnson | 138 | 140 | 116 | 93 | 127 | 121 | 105 | 89 | 116 | 112 | 109 | 86 | 100 | 99 | 100 | 72 | 78 | 82 | 80 | ||||||
| Merck & Co. Inc. | — | 117 | 124 | 116 | 126 | 135 | 120 | 107 | 129 | 138 | 138 | 118 | 123 | 126 | 116 | 93 | 106 | 106 | 113 | ||||||
| Pfizer Inc. | 209 | 186 | 207 | 192 | 224 | 202 | 188 | 173 | 207 | 173 | 155 | 120 | 124 | 113 | 91 | 63 | 94 | 96 | 96 | ||||||
| Regeneron Pharmaceuticals Inc. | 430 | 453 | 468 | 539 | 559 | 585 | 597 | 586 | 640 | 607 | 562 | 555 | 558 | 564 | 564 | 584 | 490 | 420 | 326 | ||||||
| Thermo Fisher Scientific Inc. | 108 | 106 | 103 | 98 | 112 | 110 | 104 | 97 | 112 | 107 | 105 | 101 | 111 | 112 | 106 | 97 | 111 | 116 | 118 | ||||||
| Vertex Pharmaceuticals Inc. | 410 | 338 | 338 | 333 | 335 | 304 | 274 | 242 | 229 | 211 | 190 | 166 | 154 | 137 | 131 | 112 | 150 | 120 | 122 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 469 + 93 – 149 = 413
2 Click competitor name to see calculations.
The operational efficiency regarding working capital management exhibits a significant downward trend, characterized by a substantial extension of the cash conversion cycle. From March 2022 to September 2026, the cycle expanded from 198 days to 413 days, indicating a marked increase in the time required to convert resource inputs into cash flows.
- Average Inventory Processing Period
- A consistent and aggressive upward trend is observed in inventory holding times. The period rose from 189 days in March 2022 to 469 days by September 2026. This sustained increase represents the primary driver of the lengthening cash conversion cycle, suggesting a significant accumulation of inventory or a decline in inventory turnover rates over the period.
- Average Receivable Collection Period
- The collection of receivables remained relatively stable. While fluctuations occurred—ranging from a minimum of 79 days to a peak of 103 days in June 2024—the period concluded at 93 days. This stability indicates that credit and collection policies have remained consistent and have not contributed meaningfully to the overall deterioration of the cash cycle.
- Average Payables Payment Period
- A notable increase is observed in the duration taken to settle obligations with suppliers. The payment period expanded from 70 days in March 2022 to 149 days in September 2026. This extension suggests an effort to utilize supplier financing to mitigate the liquidity pressures created by rising inventory levels.
- Cash Conversion Cycle Dynamics
- The net result of these components is a cash conversion cycle that more than doubled over the analyzed timeframe. Although the extension of the payables payment period provided a partial offset, it was insufficient to counteract the aggressive growth in the inventory processing period. Consequently, a significantly larger volume of capital is now tied up in the operating cycle than was required at the start of the period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?